Lyvgen Biopharma Holdings Limited

This early-phase study tested a new drug called LVGN6051, given alone or with the immunotherapy Keytruda, in 105 adults with advanced or spreading cancers. The main goal was to find safe doses and check for side effects. The study is complete, but results are not yet available.

This study tested a new drug (LVGN6051) combined with an existing drug (anlotinib) in 39 adults with advanced soft tissue sarcoma that had not responded to other treatments. The main goals were to check safety and find the best dose, and to see if the combination could shrink tum…

This early-stage trial tested a new drug called LVGN7409, which boosts the immune system to fight cancer. It was given alone or with other immune-boosting drugs to 66 adults with advanced cancers that had stopped responding to other treatments. The main goals were to find safe do…